Why the study?
Diabetes medications can interact with cardiorespiratory fitness, making it important to consider the influence of glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors on cardiorespiratory fitness.
Do glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors improve cardiorespiratory fitness?
Do glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors improve cardiorespiratory fitness?
There is currently a lack of robust evidence regarding the impact of GLP-1 RAs and SGLT2 inhibitors on cardiorespiratory fitness, highlighting a gap in understanding their full physiological effects.
Answers are grounded in this paper and cite their sources.
Highlights the need to monitor cardiorespiratory fitness during pharmacotherapy; leaves open whether newer agents like GL.
INTRODUCTION: Cardiorespiratory fitness (CRF) is a stronger predictor of mortality than traditional risk factors and is a neglected vital sign of health. Enhanced fitness is a cornerstone in diabetes management and is most often delivered concurrently with pharmacological agents, which can have an opposing impact, as has been reported with metformin. Considering the rapid evolution of diabetes medications with improved cardiovascular outcomes, such as glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors, it is of importance to consider the influence of these vis-a-vis effects on CRF. MATERIALS AND METHODS: Combining the words glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors with cardiorespiratory fitness, an online search was done using PubMed, Embase, Scopus, Web of Science, Scientific Electronic Library Online, and Cochrane. RESULTS: There were only a few randomized controlled studies that included CRF, and the results were mostly neutral. A handful of smaller studies detected improved CRF using sodium glucose cotransporter-2 inhibitors in patients with congestive heart failure. CONCLUSIONS: Since CRF is a superior prognosticator for cardiovascular outcomes and both medications can cause lean muscle mass loss, the current review highlights the paucity of relevant interactive analysis.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: